Core Insights - Germany's Merck KGaA has entered into a collaboration with Boston-based Valo Health to utilize its drug research services, focusing on Parkinson's and related diseases, with a potential value exceeding $3 billion [1] Company Summary - Merck KGaA is leveraging Valo Health's expertise in drug research to enhance its capabilities in developing treatments for Parkinson's disease and related conditions [1] - The collaboration signifies a strategic move by Merck KGaA to strengthen its position in the neurodegenerative disease market [1] Industry Summary - The partnership highlights the growing interest and investment in research for neurodegenerative diseases, particularly Parkinson's, which is a significant area of unmet medical need [1] - The potential financial value of the collaboration indicates a robust market opportunity for innovative drug development in this sector [1]